既往传统观念认为晚期乳腺癌是不可治愈的,但随着抗HER2药物的不断涌现,部分HER2阳性晚期乳腺癌患者通过一线曲帕双靶或大小分子组合方案、二线小分子TKI或T-DXd等抗HER2治疗可以达到CR状态,尤其是T-DXd在HER2阳性晚期乳腺癌中取得的突破性获益,使得患者生存期得到显著延长,并实现类似“治愈”的长期疾病缓解状态。 由于抗...
Luminal B breast tumors are not HER2 positive. Breast Cancer Res. 2008;10:404. Author reply 405.Bhargava R, Dabbs DJ. Luminal B Breast Tumors are not HER2 positive. Breast Cancer Res 2008;10(5):404; author reply 5.Bhargava R, Dabbs DJ. Luminal B breast tumors are not HER2 positive....
4. Francesco Perrone et al, The HOBOE-2 multicenter randomized phase 3 trial in premenopausal patients with hormone-receptor positive early breast cancer comparing Triptorelin plus Tamoxifen or Letrozole or Zoledronic acid + Letrozole.2...
乳腺癌是一种高度异质性肿瘤,内分泌疗法(ET)在Luminal型(HR+/HER2-)乳腺癌的治疗中扮演着重要的角色,主要以抑制雌激素通路为核心,阻断Luminal型乳腺癌细胞的增殖,可明显改善患者预后,但是这部分患者在ET治疗过程中又可能面临内分泌治疗耐药的难题,深挖其原因,主要与其它信号...
[4] FDA expands ribociclib indication in HR-positive, HER2-negative advanced or metastatic breast cancer | FDA [5] 2022 ASCO速递——Ribociclib带给乳腺癌患者的总生存获益再添新证,www.novartis.com.cn [6] Parati MC, Pedersini R, Perego G, Reduzzi R, Savio T, Cabiddu M, Borgonovo K, ...
Review on the Treatment of Luminal B-HER2+ Subtype Breast Cancer 引用 收藏 分享 摘要 乳腺癌是一种激素依赖性并且高度异质性的恶性肿瘤。内分泌治疗是重要治疗手段之一,尤其对于Luminal A型和Luminal B型乳腺癌患者。其中Luminal B型乳腺癌又分为Luminal B-HER2-型和Lumin...展开更多 As breast cancer is a ...
乳腺癌是一种激素依赖性并且高度异质性的恶性肿瘤.内分泌治疗是重要治疗手段之一,尤其对于Luminal A型和Luminal B型乳腺癌患者.其中Luminal B型乳腺癌又分为Luminal B-HER2-型和Luminal B-HER2+型,后者新辅助/辅助治疗上可以应用化疗,内分泌治疗以及抗HER2靶向治疗,但是部分人群对化疗不敏感,内分泌以及靶向HER2治疗耐药...
Meth-ods:The clinicopathological features and prognostic factors of 206 patients with advanced luminal B-like breast cancer treated in our hospital between June 2008 and June 2013 were retrospectively analyzed. Results:Among 206 cases, human epidermal growth factor receptor 2 (HER2) positive subtype ...
[6]DIECI M V, GUARNERI V. Should triple-positive breast cancer be recognized as a distinct subtype?. Expert Rev Anticancer Ther, 2020, 20(12): 1011-1014. [7]STATLER A B, HOBBS B P, WEI W, et al. Real-world treatment patterns and outcomes in HR+/HER2+ metastatic breast cancer pati...
We collected clinical and pathology data, and followed recurrence or matastasis of Luminal-B type breast cancer.Results Among the three subtypes of Luminal-B type breast cancer, the first group which featured HER2 positive and Ki-67 lower than 14% has the lowest lymph node metastasis rate. ...